GLP-1, Glucagon-like peptide-1
The picture is complicated by several confounding factors: Weight loss itself is associated with improved mood and reduced depressive symptoms in many individuals Better glycaemic control may enhance overall wellbeing and reduce diabetes-related distress Selection bias may exist, as patients with severe mental health conditions might be less likely to be prescribed these medications initially Currently, there is no official indication for GLP-1 agonists in treating depression, and the MHRA has not licensed these medications for mental health conditions
Dehydration from gastrointestinal side effects (nausea, vomiting, diarrhoea) may contribute to dizziness and requires adequate fluid intake
Its crucial to adhere to recommended cycle lengths (e.g., 30-60 days on, followed by an equal period off) to prevent this and maintain efficacy
These headaches can range from mild to moderate in intensity and are often transient
Plateaued Weight Loss Those who have experienced no weight loss for a period of time, even though they have been following a healthy diet and exercising regularly
